MedElevator
Войти в исследования The Australasian journal of dermatology · 2025
Nickel Contact Allergy in an Australian Patch Testing Centre Over 2014-2023.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Brasher Thomas R, Palmer Amanda, Nixon Rosemary
Аннотация
BACKGROUND: Nickel is the most common cause of allergic contact dermatitis (ACD). In certain geographical locations, the prevalence of nickel dermatitis (NiACD) has changed over time; however, there is little data on the prevalence of NiACD in Australia.
OBJECTIVES: To investigate the prevalence and trends of both nickel contact allergy and NiACD in Australia.
METHODS: A retrospective audit was performed of 3582 patients patch tested to 5% nickel sulphate between 2014 and 2023. Relevance was assessed by consultant dermatologists. Patch test data was analysed using Pearson's χ2 test and Cochran-Armitage χ2 test for trend.
RESULTS: 573/3582 (16.0%) of patients had nickel contact allergy based on positive patch tests, while 169 (4.7%) of patients were diagnosed with NiACD, where exposure to nickel correlated with their presenting dermatitis. There was a significant trend of decreasing NiACD from 2014 to 2023 (χ2 Trend (1, N = 3582) = 14.1239, PTrend = 0.0002, slope = -0.0045); however, there was no decline in the prevalence of nickel contact allergy (Pearson's χ2 test (9, N = 3582) = 13.426, p = 0.1443). Occupational NiACD was diagnosed in 20/169 (11.8%). There was a high degree of comorbid atopic dermatitis (37.3%), asthma (24.9%), and allergic rhinitis (52.1%).
CONCLUSIONS: We report a declining prevalence of NiACD but a stable prevalence of nickel contact allergy in our patient population between 2014 and 2023.
OBJECTIVES: To investigate the prevalence and trends of both nickel contact allergy and NiACD in Australia.
METHODS: A retrospective audit was performed of 3582 patients patch tested to 5% nickel sulphate between 2014 and 2023. Relevance was assessed by consultant dermatologists. Patch test data was analysed using Pearson's χ2 test and Cochran-Armitage χ2 test for trend.
RESULTS: 573/3582 (16.0%) of patients had nickel contact allergy based on positive patch tests, while 169 (4.7%) of patients were diagnosed with NiACD, where exposure to nickel correlated with their presenting dermatitis. There was a significant trend of decreasing NiACD from 2014 to 2023 (χ2 Trend (1, N = 3582) = 14.1239, PTrend = 0.0002, slope = -0.0045); however, there was no decline in the prevalence of nickel contact allergy (Pearson's χ2 test (9, N = 3582) = 13.426, p = 0.1443). Occupational NiACD was diagnosed in 20/169 (11.8%). There was a high degree of comorbid atopic dermatitis (37.3%), asthma (24.9%), and allergic rhinitis (52.1%).
CONCLUSIONS: We report a declining prevalence of NiACD but a stable prevalence of nickel contact allergy in our patient population between 2014 and 2023.